Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | LPL | P06858 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772039 | 0.81 | LPL (0.54) | LMNALPLLIPGCYP1A2CYP3A4 | |
| SCHEMBL7191487 | 0.81 | LPL (0.46) | LMNALPLLIPGCYP1A2CYP3A4 | |
| SCHEMBL13977468 | 0.79 | GCGR (0.53) | MAPTLMNAFYNBCHECYP1A2 | |
| SCHEMBL571400 | 0.76 | — | — | |
| SCHEMBL20743686 | 0.75 | PPARA (0.37) | MAPTFYNBCHELPLLIPG | |
| SCHEMBL24987295 | 0.74 | PPARA (0.59) | MAPTLMNAFYNTP53CYP1A2 | |
| SCHEMBL9728 | 0.74 | MAPT (1.00) | MAPTLMNANOTUMPABPC1APOBEC3A | |
| SCHEMBL1126802 | 0.74 | ALDH1A1 (0.50) | MAPTFYNLPLLIPGTP53 | |
| SCHEMBL28219578 | 0.74 | LPL (0.44) | LPLLIPGPPARATDO2 | |
| SCHEMBL31141579 | 0.73 | PPARA (0.63) | MAPTLMNAFYNTP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706149-A2 | LIPOSOME COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS | ALZA CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7112337-B2 | Liposome composition for delivery of nucleic acid | ALZA CORPORATION (US) | 2006-09-26 | — | — | US | disclosed |
| US-20050191344-A1 | Liposome composition for delivery of therapeutic agents | ALZA CORPORATION | 2005-09-01 | — | — | US | disclosed |
| WO-2005070466-A2 | LIPOSOME COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS | ALZA CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
| CN-1617710-A | Liposome composition for delivery of nucleic acid | ALZA CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| EP-1465599-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040197390-A1 | Neutral-cationic lipid for systemic delivery of factor VIII gene | HUANG SHI-KUN (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040166150-A1 | Neutral-cationic lipid for systemic delivery of Factor VIII gene | HUANG SHI-KUN (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2003053409-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030031704-A1 | Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic | ALZA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| WO-2002096390-A1 | NEUTRAL-CATIONIC LIPID FOR SYSTEMIC DELIVERY OF FACTOR VIII GENE | ALZA CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| CN-1233237-A | Heteroaryl succinamides and their use as metalloproteinase inhibitors | AGOURON PHARMA (US) | 1999-10-27 | — | — | CN | disclosed |
| EP-0937042-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998017643-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197390-A1 | Neutral-cationic lipid for systemic delivery of factor VIII gene | F13B, F13A1, F8 | MAPT 4482/4885LMNA 1069/4885FYN 3668/4885 |
| US-20050191344-A1 | Liposome composition for delivery of therapeutic agents | PHOSPHO1, LIPA, SGMS1 | MAPT 2621/4885LMNA 32/4885FYN 4449/4885 |
| US-20030031704-A1 | Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic | DLST, LIPA, DNAJC10 | MAPT 3499/4885LMNA 270/4885FYN 3323/4885 |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | MAPT 4640/4885LMNA 1232/4885FYN 2795/4885 |
| US-20040166150-A1 | Neutral-cationic lipid for systemic delivery of Factor VIII gene | F8, F13B, F13A1 | MAPT 4789/4885LMNA 736/4885FYN 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.